98%
921
2 minutes
20
Autophagy, an evolutionarily conserved process, plays an important role in cellular homeostasis and human diseases. Cardiovascular dysfunction, which presents during cancer treatment or in cancer-free individuals years after treatment, is a growing clinical challenge. Millions of cancer survivors and patients face an unpredictable risk of developing cardiotoxicity. Cardiotoxicity due to cancer treatment, as well as cancer progression, has been linked to autophagy dysregulation. Modulating autophagy has been further proposed as a therapeutic treatment for both cancer and cardiovascular disorders. The safe and effective use of autophagy modulation as a cardioprotective strategy during cancer treatment especially requires careful consideration and experimentation to minimize the impact on cancer treatment. We focus here on recent advances in targeted autophagy modulation strategies that utilize interdisciplinary approaches in biomedical sciences and are potentially translatable to treat cardiotoxicity and improve cancer treatment outcomes. This review highlights non-small molecule autophagy modulators to enhance targeted therapy, nanomedicine for autophagy modulation and monitoring, and in vitro models and future experiments needed to bring novel autophagy discoveries from basic research to clinical translation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12114528 | PMC |
http://dx.doi.org/10.3390/ph18050671 | DOI Listing |
J Appl Clin Med Phys
September 2025
Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia, USA.
Purpose: Real‑time magnetic resonance-guided radiation therapy (MRgRT) integrates MRI with a linear accelerator (Linac) for gating and adaptive radiotherapy, which requires robust image‑quality assurance over a large field of view (FOV). Specialized phantoms capable of accommodating this extensive FOV are therefore essential. This study compares the performance of four commercial MRI phantoms on a 0.
View Article and Find Full Text PDFJ Appl Clin Med Phys
September 2025
Icon Cancer Centre Toowoomba, Toowoomba, Queensland, Australia.
Introduction: The role of imaging in radiotherapy is becoming increasingly important. Verification of imaging parameters prior to treatment planning is essential for safe and effective clinical practice.
Methods: This study described the development and clinical implementation of ImageCompliance, an automated, GUI-based script designed to verify and enforce correct CT and MRI parameters during radiotherapy planning.
J Appl Clin Med Phys
September 2025
Department of Radiation Oncology, University of Utah, Salt Lake City, Utah, USA.
Purpose: The development of on-board cone-beam computed tomography (CBCT) has led to improved target localization and evaluation of patient anatomical change throughout the course of radiation therapy. HyperSight, a newly developed on-board CBCT platform by Varian, has been shown to improve image quality and HU fidelity relative to conventional CBCT. The purpose of this study is to benchmark the dose calculation accuracy of Varian's HyperSight cone-beam computed tomography (CBCT) on the Halcyon platform relative to fan-beam CT-based dose calculations and to perform end-to-end testing of HyperSight CBCT-only based treatment planning.
View Article and Find Full Text PDFEur J Med Res
September 2025
Department of Zoology, Faculty of Science, Ain Shams University, Abbassia, Cairo, 11566, Egypt.
Nuclear receptors (NRs) are a superfamily of ligand-activated transcription factors that regulate gene expression in response to metabolic, hormonal, and environmental signals. These receptors play a critical role in metabolic homeostasis, inflammation, immune function, and disease pathogenesis, positioning them as key therapeutic targets. This review explores the mechanistic roles of NRs such as PPARs, FXR, LXR, and thyroid hormone receptors (THRs) in regulating lipid and glucose metabolism, energy expenditure, cardiovascular health, and neurodegeneration.
View Article and Find Full Text PDFGenome Biol
September 2025
Department of Clinical Pharmacy, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, 90089, USA.
Background: Recent advances in high-throughput sequencing technologies have enabled the collection and sharing of a massive amount of omics data, along with its associated metadata-descriptive information that contextualizes the data, including phenotypic traits and experimental design. Enhancing metadata availability is critical to ensure data reusability and reproducibility and to facilitate novel biomedical discoveries through effective data reuse. Yet, incomplete metadata accompanying public omics data may hinder reproducibility and reusability and limit secondary analyses.
View Article and Find Full Text PDF